Search Results for: Research
Why is Vitamin K2 as MK-7 an essential nutrient for supporting cardiovascular health ? Check out this new video to find out. Gnosis by Lesaffre wants to create a healthier global population, and that starts with securing our cardiovascular health. MenaQ7® is the premium Vitamin K2 as MK-7 clinically proven to simultaneously support heart … Continue reading New MenaQ7® Heart Health Video
Why is Vitamin K2 as MK-7 an essential nutrient for supporting cardiovascular health ? Check out this new video to find out.
Gnosis by Lesaffre wants to create a healthier global population, and that starts with securing our cardiovascular health.
MenaQ7® is the premium Vitamin K2 as MK-7 clinically proven to simultaneously support heart and bone health by activating Vitamin K-dependent proteins already in the body. Where cardiovascular health is concerned, Matrix Gla Protein (MGP) is the most potent inhibitor of vascular calcification, but it needs adequate Vitamin K2 to activate it.
Learn more about MenaQ7® and the substantial research confirming its integral role in supporting heart health.
VETA Trial will evaluate the therapeutic effect of vitamins K2 and D3 paired with Empagliflozin on various diabetic and quality-of-life parameters. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (8 Sept 2022) – A new study protocol1 has been published on ClinicalTrials.gov (NCT05417880) detailing a trial initiated by Gnosis by Lesaffre partner Scotmann Pharmaceuticals, … Continue reading NEW VITAMIN K2 CLINICAL TRIAL ANNOUNCED
VETA Trial will evaluate the therapeutic effect of vitamins K2 and D3 paired with Empagliflozin on various diabetic and quality-of-life parameters.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (8 Sept 2022) – A new study protocol1 has been published on ClinicalTrials.gov (NCT05417880) detailing a trial initiated by Gnosis by Lesaffre partner Scotmann Pharmaceuticals, Pakistan, who will execute a large-scale, multi-centered study to examine the impact of the combination of Empagliflozin, an oral anti-diabetic, with vitamins K2 and D3 on various diabetic parameters, including quality-of-life. Scotmann Pharmaceuticals, Pakistan uses Gnosis by Lesaffre’s vitamin K2 MK7 from natural fermentation, which has been validated in numerous clinical trials.
Globally, there were 437.9 million prevalent cases of Type 2 Diabetes in 2019, with an age-standarized point prevalence of 5,282.9 per 100,000 populations, which represents a 49% increase since 1990.2 The VETA Trial (Vitamin D, K2 plus Empagliflozin combination in Type Two Diabetes Mellitus) is a six-month prospective, randomized, controlled, open-label, multicenter trial conducted in collaboration with the University of Health Sciences Lahore (Pakistan) and the Pakistan Society of Internal Medicine. The study will enroll 340 participants, aged 40-60 years and having Type 2 Diabetes Mellitus (T2DM) for at least 10 years.
The participants will be allocated to either: the control group (continuing current oral anti-hyperglycemic other than SGLT2 inhibitors and no added D3 or K2 supplementation), the interventional groups receiving either 10mg Empagliflozin (a medication used together with diet and exercise to treat Type 2 diabetes; as VORETA tablets) or 10mg Empagliflozin plus the combination of 2,000 IUs of vitamin D3 and 100 mcg of Vitamin K2 as MK7 (as SunnyD PRO soft gel). The doses of both Empagliflozin tablets and the combination D3 + K2 soft gel will be taken once daily.
The main goals of the study are to:
- Explore the effects on hyperglycemic parameters (including HbA1c, FBS and RBS)
- Explore the effects on hyperlipidemic parameters (including HDL-C, LDL-C and Triglycerides)
- Assess the improvements in Diabetic Quality of Life parameters (DQol)
- Explore the effects on arterial calcification markers
“The idea is to follow the holistic approach guidelines for the management of T2DM,” says Dr. Syeda Saba Alsam, Head of Medical Affairs and Research with Scotmann Pharmaceuticals, Pakistan, noting that baseline screening of serum 25(OH)D3 levels would be done on all patients. “Since Vitamin D deficiency is highly prevalent in this cohort and a typical Pakistani diet lacks Vitamin K2, we are exploring the potential beneficial effects of these two micronutrients in Diabetic patients.”
“While treatment is crucial for diabetes, the proper nutrient intake is also important for this group of patients. Deficiency of vitamin D is globally recognized; however, the research suggests that vitamin D3 should be combined with vitamin K2 for synergistic impact. Further, it has been shown that vitamin K2 supplementation can effectively improve clinical features of diabetes,” says Sophie Legrain, Gnosis by Lesaffre Director of R&D, noting a study3 that showed vitamin K2 intake, specifically, produced a 7% reduction in T2DM risk with each 10mcg increment. “It is exciting to see our partner exploring the impact K2 and D3 could have for patients adding it to their therapy.”
References:
1https://clinicaltrials.gov/ct2/show/NCT05417880?term=vitamin+k2&draw=2
2 Safiri S et al. Prevalence, Deaths and Disabiity-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and its Attributable Risk Factors in 204 Countries and Territories, 1990-2-19: Results from the Global Buden of Disease Study 2019. Front. Endocrinol., 25 Feb 2022. 13:838027.
3 Beulens JW, et al. Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care. 2010;33:1699–705.
About Scotmann Pharmaceuticals, Pakistan
Scotmann is a pharmaceutical centre of excellence with a diversified portfolio of branded generics in biotech, cardiovascular, diabetes, gastroenterology, respiratory, inflammatory diseases, pain management, osteoporosis, psychiatry, and OTC segments. The company’s R&D is structured around partnerships with European Contract Research Organizations (CROs). These partnerships help Scotmann adhere to excellent manufacturing practices, ensuring that its products meet the highest international standards for safety and efficacy.
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
VIKIPEDIA Trial using 1mg MenaQ7® K2 as MK-7 was the centerpiece of a presentation at the 10th Annual Nephrology Symposium 2022 in Greece. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (5 JANUARY 2023) – A presentation at the 10th Annual Nephrology Symposium 2022, an event organized by the Academy of Nephrology & Nephrology Clinic … Continue reading VITAMIN K2 IMPORTANCE FOR CARDIO HEALTH HIGHLIGHTED AT NEPHROLOGY SYMPOSIUM
VIKIPEDIA Trial using 1mg MenaQ7® K2 as MK-7 was the centerpiece of a presentation at the 10th Annual Nephrology Symposium 2022 in Greece.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (5 JANUARY 2023) – A presentation at the 10th Annual Nephrology Symposium 2022, an event organized by the Academy of Nephrology & Nephrology Clinic of the University General Hospital of Larissa, Department of Medicine of the University of Thessaly, discussed the important role vitamin K2 plays in vascular calcification and the potential impact for chronic kidney disease patients. A core element of the presentation was a discussion of the current VIKIPEDIA Trial, which uses the highest dosage of MenaQ7Ò Vitamin K2 as MK-7 to date: 1 mg daily.
The Nephrology Symposium covers modern scientific developments in kidney diseases related to diagnosis, prevention, and treatment. According to event organizers, the main goal of the event is to contribute to more effective and correct treatment of kidney diseases. The program was attended by distinguished scientists from Greece and abroad with renowned clinical and research work in Nephrology and other fields of medicine.
One of those esteemed presenters was Stefanos Roumeliotis, MD, PhD, lead researcher of the multi-center, placebo-controlled, randomized, open-label intervention clinical trial “The Effect of Vitamin K2 Supplementation on Arterial stiffness and Cardiovascular Events in PEritonial DIAlysis (VIKIPEDIA)”. Dr. Roumeliotis and his colleagues at Aristotle University of Thessoloniki in Greece are studying the effect of K2 supplementation (through the normalization of dp-ucMGP) on arterial stiffness and the occurrence of cardiovascular events.
“Cardiovascular disease is the main cause of death in end-stage kidney disease patients undergoing maintenance dialysis, mainly due to accelerated vascular calcification. Having this in mind, it is crucial to investigate possible novel therapeutic choices to abrogate vascular calcification in these patients,” he explains. “Exogenous supplementation of vitamin K2 in dialysis patients has proven to be safe and well tolerated. This present study aims to elucidate whether increased vitamin K intake in peritoneal dialysis patients might be of cardiovascular benefit.
“VIKIPEDIA is the first study to assess whether a high dosage of menaquinone-7 could improve arterial stiffness, mortality, cardiovascular disease, 24-hour ambulatory blood pressure, and dialysis efficacy in patients with peritoneal dialysis,” Dr. Roumeliotis adds. “MenaQ7 was chosen to be used in the study because the compound showed its efficacy to improve vitamin K status in many clinical trials with kidney patients.”
The protocol for the 1.5-year study published in June 2021, and researchers will collaborate with renowned vitamin K researchers and Gnosis by Lesaffre research partner Maastricht University, the Netherlands.
“The implications of vitamin K2 being a part of this symposium are immeasurable,” says Sophie Legrain, Gnosis by Lesaffre Director of R&D. “It cannot be overstated the importance of every possible opportunity to advance industry, academic, and medical understanding of this essential nutrient. The VIKIPEDIA Trial using such a high dosage of our MenaQ7 K2 supports its high safety profile, and we are excited at the potential positive results can offer for an at-risk patient population.”
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and well-being. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
About Lesaffre
A key global player in fermentation for more than a century, Lesaffre, with a 2.2 billion euro turnover, and established on all continents, counts 10,700 employees and more than 70 nationalities. On the strength of this experience and diversity, we work with customers, partners, and researchers to find ever more relevant answers to the needs of food, health, naturalness, and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms.
To nourish 10 billion people, in a healthy way, in 2050 by making the most of our planet’s resources is a major and unprecedented issue. We believe fermentation is one of the most promising answers to this challenge.
Lesaffre – Working together to better nourish and protect the planet.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com
2022 Supplement Consumer Survey validates K2 sales growth, identifying younger demographics seeking core benefits and focusing on branded ingredients. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (XX July 2022) – The Industry Transparency Center announced a new survey of 3,500 dietary supplement consumers. The “ITC Insights – 2022 Supplement Consumer Survey” was conducted … Continue reading VITAMIN K2 USE, AWARENESS CONTINUES TO GROW: NEW CONSUMER SURVEY
2022 Supplement Consumer Survey validates K2 sales growth, identifying younger demographics seeking core benefits and focusing on branded ingredients.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (XX July 2022) – The Industry Transparency Center announced a new survey of 3,500 dietary supplement consumers. The “ITC Insights – 2022 Supplement Consumer Survey” was conducted by Dynata from March 1-26, 2022, and was written and analyzed by the Industry Transparency Center. The breakdown of supplement consumers included 1,000 from the US, 1,000 from China, 500 from the UK, 500 from Germany, and 500 from Italy. Participants identifying as Female represented 52% of respondents, and Men represented 48% of respondents. Ages ranged from 18 to 65+ years.
Key Findings from the Survey:
- 63% reported, “I am proactive about my health and take steps to lower health risks,” while 76% said, “I use/have used vitamins, minerals, herbs or other dietary supplements to help manage my health.”
- 62% reported using Vitamin K2 supplements, ranking in the top 10 ingredients used.
- The 18 – 54 age group brackets showed an increase in usage of Vitamin K2 compared to those 55+.
- No single supplement increased usage across every country; however, Vitamin K2 was one of the closest to achieving universal growth. K2 also saw a sharp increase in use from 2020-2022.
- “Perceived effectiveness” of K2 was greater in total supplement users surveyed compared to “regular users.” This suggests to the researchers that future growth is likely as people who do not currently use Vitamin K2 regularly have a high perception of it.
- For supplement users of branded ingredients, “Quality,” “Safety,” “Trust,” “Efficacy,” and “Clinical Validation” ranked as the top 5 reasons for use.
- Bone Health and Heart Health ranked as the top reasons for using Vitamin K2, especially for regular users. While irregular users noted various reasons, including “bioavailability of other supplements.”
- Brain Health and Mental Acuity also ranked relatively high and have a low gap between irregular and regular users. Researchers believe this partially confirms “the earlier hypothesis of potential opportunities in this area.”
“This survey confirms what we see commercially in many ways. Consumers have a high trust and interest in Vitamin K2, especially those looking for specific health benefits,” according to Xavier Berger, Global Market Manager with Gnosis by Lesaffre. “It is also nice to see that ‘quality,’ ‘efficacy’ (i.e., proof that it works), and ‘safety’ are recognized in the branded ingredients. MenaQ7 is a standout Vitamin K2 in this regard, as it is the only K2 as MK-7 with clinical validation confirming bone and cardiovascular benefits.”
Interestingly, 37% of regular users responded that they always look for branded ingredients and are willing to pay a premium, with an additional 22% looking for them but not willing to pay a premium. While nearly 60% of Vitamin K2 users are looking for branded ingredients, products utilizing these premium materials represent a competitive edge.
Berger added, “Very interesting is that 67% of consumers said they look for a specific Vitamin K2 brand while purchasing their supplements, and our two brands – MenaQ7 K2 as MK-7 and vitaMK7 – are in the top 3 brands most sought out.”
The General Criteria for Participation included Supplement users and qualification questions that corrected for participants who proclaimed they were ‘not a user’ in questioning.
# # #
About the Industry Transparency Center
The Industry Transparency Center (ITC) is a strategy and insights firm driving transparency in the health ingredients and natural products industries through four key pillars: Insights, Stewardship, Strategy, and Community. ITC provides guidance to organizations across the globe via strategic insights, category stewardship, world-class events and thought leadership. ITC also operates the Global Prebiotic Association, Global Curcumin Association, Collagen Stewardship Alliance and Coconut Coalition of the Americas. Learn more at ITCStrategy.com
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
IECN 2022 poster presentation highlights the non-canonical role of MenaQ7® Vitamin K2 on vascular calcification, widening cardio evidence and potential sports applications. MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (29 MAR 2022) – A poster presented 25 March 2022 at the 2nd International Electronic Conference on Nutrients (IECN) detailed recent research showing that … Continue reading Vitamin K2 Impact on Oxidative Stress, ATP Production: New Evidence
IECN 2022 poster presentation highlights the non-canonical role of MenaQ7® Vitamin K2 on vascular calcification, widening cardio evidence and potential sports applications.
MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (29 MAR 2022) – A poster presented 25 March 2022 at the 2nd International Electronic Conference on Nutrients (IECN) detailed recent research showing that MenaQ7® Vitamin K2 as MK-7 countered induced oxidative stress in vascular smooth muscle cells, ultimately lowering oxidative stress while increasing ATP production. The global event focuses on nutrition support for immunity and countermeasure effects on infection, inflammation, and oxidative stress.
The poster, “Non-Canonical Role of MK-7 in Vascular Smooth Muscle Cells” [1], was presented to the prestigious audience by PhD student Asim Cengiz Akbulut, Department of Biochemistry, CARIM, Maastricht University, with the support of his supervisor and senior author on the abstract Prof. Leon Schurgers, Professor of Biochemistry of Vascular Calcification and Vice-Chair of Biochemistry at CARIM, Maastricht University. Akbulut shared recent findings from a cellular study where the vitamin K pathway was antagonized by warfarin, inducing oxidative stress in vascular smooth muscle cells (SMCs), contributing to pathological phenotype perpetuating vascular calcification and cardiovascular disease.
After introducing Vitamin K2 as MK-7 (as MenaQ7®), measurements were taken of ATP, oxidative stress, extracellular vesicles (EV). Key findings include: interference with vitamin K metabolism by warfarin results in increased intracellular oxidative stress and EV secretion, MK7 counteracts intracellular oxidative stress, both under normal conditions and warfarin-induced, and MK7 increases ATP (adenosine triphosphate) production, even in the presence of warfarin.
The authors concluded: “Our experiments show that in primary human SMCs, MK-7 lowers oxidative stress and EV release and increases ATP production. This pathway points to a non-canonical role of MK-7 in the prevention of vascular calcification, unrelated to its canonical role as cofactor for the posttranslational modification of MGP.”
Since 2004, NattoPharma (now Gnosis by Lesaffre) has worked closely with the Maastricht University in documenting the benefits of the company’s exclusive vitamin K2 as MK-7 brand MenaQ7®. These new findings are in line with previous research eliminating that vitamin K2 decreases oxidative stress[2], as well as the non-canonical role of K2 inhibiting inflammatory markers[3].
“We are incredibly encouraged by the results of this study highlighting the potential of Vitamin K2 as MK-7 for healthy aging, as oxidative stress is involved in several age-related conditions, such as increased cardiovascular risk, chronic kidney conditions, and neurodegenerative disorders,” explains Hogne Vik, Gnosis by Lesaffre Chief Medical Officer. “This contributes nicely to our already substantial body of research showing MenaQ7 is a cardio-protective nutrient and reaffirms why the medical community is interested in the ongoing study of this important nutrient for the betterment of global health.
“Further, evidence showing MenaQ7 increased the production of ATP shines highlights K2 as MK-7 as a potentially essential nutrient for sports nutrition,” concludes Vik. “While it is preliminary data, we are excited about the next steps of this important research to validate the additional health benefits and applications.”
# # #
References:
1 https://sciforum.net/paper/view/12401
2 https://www.atherosclerosis-journal.com/article/S0021-9150(19)31253-5/fulltext
3 https://pubmed.ncbi.nlm.nih.gov/27200471/
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and applications capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
New evidence draws an association between Vitamin K insufficiency and cognitive dysfunction, further argument for the potential of Vitamin K2. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (26 APRIL 2022) – Frontiers in Nutrition published a new large-population cross-sectional study that demonstrated the association of vitamin K insufficiency with cognitive function. In … Continue reading VIT K INSUFFICIENCY LINKED TO BRAIN HEALTH: NEW PAPER
New evidence draws an association between Vitamin K insufficiency and cognitive dysfunction, further argument for the potential of Vitamin K2.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (26 APRIL 2022) – Frontiers in Nutrition published a new large-population cross-sectional study that demonstrated the association of vitamin K insufficiency with cognitive function.
In the study, “Association of Vitamin K Insufficiency with Cognitive Dysfunction in Community-Dwelling Older Adults”[1], Japanese researchers enrolled a total of 800 community-dwelling older adults (mean age = 75.9) and conducted a geriatric health examination, including a Mini-Mental State Examination (MMSE) and a blood test. Examining the concentration of undercarboxylated osteocalcin (ucOC) in serum, which is a biomarker for vitamin K insufficiency, they demonstrated the association of the concentration of undercarboxylated osteocalcin (ucOC) in serum, which is a biomarker for vitamin K insufficiency, with cognitive function. By using binary logistic regression analysis, the risk of cognitive impairment equivalent or below the mild cognitive impairment level for each tertile of ucOC was examined, with the lowest tertile as the reference.
The results showed a significant association of impaired cognitive function and concentration of ucOC in the highest tertile of ucOC, with the odds ratio of 1.65 (95% CI, 1.06 to 2.59, P = 0.028). When the analysis was repeated with each domain of MMSE score*, the highest tertile of ucOC was associated with impaired orientation, calculation, and language.
The finding of the present study was in line with the previous epidemiological studies, showing that lower vitamin K intake is associated with cognitive impairment. The researchers reported, “As far as we know, this is the first report on the significant association of single ucOC measurement and cognitive impairment. Our analysis also suggests that vitamin K insufficiency could be associated with selected categories of cognitive function. Since the single measurement of ucOC in serum is a simple and widely available method for vitamin K evaluation, it could be useful as a biomarker of neurodegenerative diseases affecting the cognitive functions.”
These results are supported by another recently published paper from Spain[2] that assessed two years of changes in dietary K intake with cognitive function measured through neuropsychological performance tests. The researchers concluded that “An increase of the intake of dietary vitamin K was associated with better cognitive function scores, independently of recognized risk factors for cognitive decline, in an older adult Mediterranean population with high cardiovascular risk.”
While the Japanese study examined “vitamin K,” there are several studies that showed that MenaQ7® Vitamin K2 as MK-7 improved K status as measured by ucOC, and these were done in healthy adult and child populations.[3,4]
“We have worked with world-renowned researchers – as NattoPharma and that work continues at Gnosis by Lesaffre – to confirm the safe and effective health benefits of MenaQ7 Vitamin K2 as MK-7. Elucidating the important mechanism of activating K-dependent proteins, including osteocalcin and Matrix Gla protein (MGP), was a foundational piece of that work,” explains Dr. Hogne Vik, chief medical officer with Gnosis by Lesaffre, who referenced an important 2021 US-based review paper highlighting Vitamin K2 as a potential strategy for Alzheimer’s disease.[5] “Based on our research and the critical work that continues, we can hypothesize that K2 supplementation could prove beneficial in the brain development of children and support healthy brain function in adults.”
Dr. Vik also noted that while Vitamin K2 as MK-4 has been noted as the main form of vitamin K in the brain, “it is important to mention that in-vivo research supports that supplementation with K2 as MK-7 increases MK-4 content in the brain tissue,” he concluded.
# # #
References:
1 Azuma K et al. Association of Vitamin K Insufficiency With Cognitive Dysfunction in Community-Dwelling Older Adults. Front. Nutr. (2022) 8:811831. doi: 10.3389/fnut.2021.811831
2 Camacho-Barcia L et al. Vitamin K dietary intake is associated with cognitive function in an older adult
Mediterranean population. Age Ageing. 2022 Feb 2;51(2):afab246. Doi: 10.1093/ageing/afab246.
3 Knapen MHJ et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013 Sep;24(9):2499-507. doi: 10.1007/s00198-013-2325-6. Epub 2013 Mar 23. PMID: 23525894.
4 Theuwissen E et al. Vitamin K status in healthy volunteers. Food Funct. 2014 Feb;5(2):229-34. doi: 10.1039/c3fo60464k. PMID: 24296867.
5 Popescu A and German M. “Vitamin K2 Holds Promise for Alzheimer’s Prevention and Treatment.” Nutrients. 2021,13,2206.
* Explanation of MMSE: The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia. On average, the MMSE score of a person with Alzheimer’s declines about 2 to 4 points each year.
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and applications capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220